Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.
Siddharth Padia, MD, a specialist in vascular and interventional radiology at the University of California, Los Angeles Medical Center, discusses the utility of TheraSphere™ Yttrium-90 (Y-90) Glass Microspheres in patients with hepatocellular carcinoma (HCC).
The development of radioembolization and Y-90 for patients with HCC, through the efforts of multiple centers, countries, and clinical trials such as the TARGET trial (NCT03295006), has yielded positive and consistent findings, according to Padia. Y-90 has proven to be a highly efficacious and well-tolerated therapy, demonstrating promising 2- and 3-year overall survivals, he says.
Additionally, Y-90 does not prevent patients from receiving downstream treatments such as systemic therapies, including immune checkpoint inhibitors, or TKIs. It can also be used as a solo destination therapy, a bridge or downstage therapy to surgical resection or transplantation, in combination with systemic agents, or as a bridge to systemic therapy, Padia concludes.